ReviewFrontiers in immunology2020
Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- MicroRNAs as Diagnostic Biomarkers of Myasthenia Gravis: A Systematic Review and Meta-Analysis.Cellular and molecular neurobiology · 2025Pooled it
- Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study.PloS one · 2026Article
- Hsa_circ_0000313/miR-1224-3p/MKNK2 Axis Modulates CD4Mediators of inflammation · 2026Article
- Immunological Targets in Generalized Myasthenia Gravis Treatment: Where Are We Going Now?Brain sciences · 2025Review
- Acute endothelial stresses identify microRNA let-7b-5p and non-coding SLC11A2 (NRAMP2/DMT1) exon as biomarkers that overlap with those detected in malignant and non-malignant diseases.QJM : monthly journal of the Association of Physicians · 2025Article
- Plasma Biomarkers of Mitochondrial Dysfunction in Patients with Myasthenia Gravis.Medical sciences (Basel, Switzerland) · 2025Article
- Recent advances in the development and clinical application of miRNAs in infectious diseases.Non-coding RNA research · 2025Review
- Ocular myasthenia gravis management.Frontiers in neurology · 2025Review
- Decoding myasthenia gravis: advanced diagnosis with infrared spectroscopy and machine learning.Scientific reports · 2024Article
- Article
- Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy.European journal of neurology · 2024Review
- Identification and verification of inflammatory biomarkers for primary Sjögren's syndrome.Clinical rheumatology · 2024Article
- Cell Type-Specific Extracellular Vesicles and Their Impact on Health and Disease.International journal of molecular sciences · 2024Review
- Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis.Frontiers in molecular biosciences · 2024Review
- Physiological and pathological roles of the thymus and value of thymectomy in myasthenia gravis: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Review
- miRNAs as the important regulators of myasthenia gravis: involvement of major cytokines and immune cells.Immunologic research · 2023Review
- Evidence for Existence of Multiple Functional Human Small RNAs Derived from Transcripts of Protein-Coding Genes.International journal of molecular sciences · 2023Article
- Molecular and biochemical investigations of the anti-fatigue effects of tea polyphenols and fruit extracts ofFrontiers in molecular biosciences · 2023Article
- Ocular Myasthenia Gravis: A Current Overview.Eye and brain · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies which attack receptors at the neuromuscular junction. One of the main difficulties in predicting the clinical course of MG is the heterogeneity of the disease, where disease progression differs greatly depending on the subgroup that the patient is classified into. MG subgroups are classified according to: age of onset [early-onset MG (EOMG; onset ≤ 50 years)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.